Search results
Showing 1851 to 1900 of 4091 results for patient
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy.
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Recommendation ID NG24/4 Question Fresh frozen plasma for patients with abnormal haemostasis who are having invasive procedures or...
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation
Diabetes: lipid-lowering therapies for primary prevention of CVD (40 years and over) (IND275)
This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a lipid-lowering therapy (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk) (IND274)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
comparative studies against existing forms of management. Studies should record patient selection, functional outcomes, quality of life...
Mechanical clot retrieval for treating acute ischaemic stroke (HTG403)
Evidence-based recommendations on mechanical clot retrieval for treating acute ischaemic stroke in adults. This involves using a device to remove the blood clot from the brain to restore normal blood flow.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)
NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery .
Evidence-based recommendations on endovascular closure of patent ductus arteriosus. This involves placing a blocking device into the heart, which stays in place permanently and the body’s tissue grows around it.
View recommendations for HTG59Show all sections
Sections for HTG59
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for HTG685Show all sections
Supraorbital minicraniotomy for intracranial aneurysm (HTG52)
Evidence-based recommendations on supraorbital minicraniotomy for intracranial aneurysm. This involves clipping or wrapping the aneurysm through a smaller opening made in the skull, above the eyebrow.
View recommendations for HTG52Show all sections
Sections for HTG52
Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.
View recommendations for HTG480Show all sections
same mission: helping practitioners and commissioners get the best care to patients fast, while ensuring value for the taxpayer. To...
How to use NICE guidance to reduce health inequalities during and after pregnancy.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Mini/micro screw implantation for orthodontic anchorage (HTG152)
Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.
View recommendations for HTG152Show all sections
Sections for HTG152
Evidence-based recommendations on microwave ablation of hepatocellular carcinoma. This involves using heat from microwave energy to destroy the cancer cells.
View recommendations for HTG138Show all sections
Sections for HTG138
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
Evidence-based recommendations on intraoperative blood cell salvage in obstetrics. This involves filtering and washing shed blood and retransfusing it during or after the procedure.
View recommendations for HTG90Show all sections
Sections for HTG90
Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.
View recommendations for HTG9Show all sections
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)
NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
View quality statements for QS68Show all sections
Sections for QS68
- Quality statements
- Quality statement 1: Diagnosis of acute myocardial infarction
- Quality statement 2: Risk assessment for adults with NSTEMI or unstable angina
- Quality statement 3: Coronary angiography and PCI within 72 hours for NSTEMI or unstable angina
- Quality statement 4: Coronary angiography and PCI for adults with NSTEMI or unstable angina who are clinically unstable
- Quality statement 5: Level of consciousness and eligibility for coronary angiography and primary PCI
- Quality statement 6: Primary PCI for acute STEMI
- Update information
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (HTG66)
Evidence-based recommendations on artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis. This involves removing the diseased joints and replacing them with artificial ones.
View recommendations for HTG66Show all sections
Sections for HTG66